No quarterly revenue total was found in CONTEXT THERAPEUTICS INC.'s SEC filings.
Context Therapeutics Inc. (CNTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$7.0 million. As of Jun 30, 2026 it held $43.0 million in cash and investments and $200,000 in total debt.
Revenue
—
Net income
$-14.56M
-64.9% vs year-ago quarter
Operating cash flow
$-7.02M
-20.3% vs year-ago quarter
Free cash flow
$-7.04M
-20.6% vs year-ago quarter
EPS
$-0.15
-66.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
91.88M
+2.4% vs year-ago quarter
Net cash
$42.79M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CNTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Philadelphia, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1842952
- Former names
- Context Therapeutics LLC (until May 3, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$15.0M | -$9.3M | -$13.8M | -$10.6M | -$9.8M |
| Net income | -$14.6M | -$8.7M | -$13.0M | -$9.7M | -$8.8M |
| Diluted EPS | -$0.15 | -$0.09 | -$0.14 | -$0.10 | -$0.09 |
| Operating cash flow | -$7.0M | -$11.4M | -$8.9M | -$6.6M | -$5.8M |
| Free cash flow | -$7.0M | -$11.5M | -$8.9M | -$6.6M | -$5.8M |
| Total assets | $46.1M | $58.9M | $68.5M | $79.2M | $87.2M |
| Total liabilities | $8.0M | $6.7M | $8.0M | $6.1M | $4.6M |
| Stockholders' equity | $38.2M | $52.2M | $60.5M | $73.2M | $82.5M |
| Cash and investments | $43.0M | $54.5M | $66.0M | $76.9M | $83.5M |
| Total debt | $200,000 | $300,000 | $100,000 | $100,000 | $200,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Aug 5, 2026 | Aug 5, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 31, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 26, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 15, 2026 | Jun 15, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
May 18, 2026 | May 14, 2026 |
All 307 Context Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.